1.08
Pds Biotechnology Corporation stock is traded at $1.08, with a volume of 484.44K.
It is down -9.24% in the last 24 hours and down -18.80% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$1.19
Open:
$1.17
24h Volume:
484.44K
Relative Volume:
0.80
Market Cap:
$48.16M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-0.9231
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
-18.18%
1M Performance:
-18.80%
6M Performance:
-70.41%
1Y Performance:
-73.13%
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PDSB
Pds Biotechnology Corporation
|
1.08 | 48.16M | 0 | -40.56M | -35.28M | -1.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-01-22 | Initiated | B. Riley Securities | Buy |
Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
May-27-20 | Initiated | Alliance Global Partners | Buy |
Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
Virtu Financial LLC Takes $89,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call Transcript - MSN
PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish - Asianet Newsable
HC Wainwright Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price - Defense World
H.C. Wainwright cuts PDS Biotechnology stock target to $13 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts PDS Biotechnology stock target to $13 - Investing.com India
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
PDS Biotechnology Advances Cancer Immunotherapy Trials - TipRanks
Earnings call transcript: PDS Biotech Q4 2024 shows narrowed loss, stock rises By Investing.com - Investing.com South Africa
PDS Biotech commences phase 3 trial for HPV cancer therapy By Investing.com - Investing.com South Africa
PDS Biotech commences phase 3 trial for HPV cancer therapy - Investing.com
PDS Biotech Advances Cancer Immunotherapy with New Clinical Trial - TipRanks
Earnings call transcript: PDS Biotech Q4 2024 shows narrowed loss, stock rises - Investing.com
PDS Biotechnology Corp reports results for the quarter ended December 31Earnings Summary - TradingView
PDS BIOTECHNOLOGY Earnings Results: $PDSB Reports Quarterly Earnings - Nasdaq
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update - MarketScreener
A Look at PDS Biotechnology's Upcoming Earnings Report - Benzinga
PDS Biotechnology Corp expected to post a loss of 28 cents a shareEarnings Preview - TradingView
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference - TradingView
PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts - Insider Monkey
10 Penny Stocks With Huge Upside Potential According To Analysts - Insider Monkey
PDS Biotechnology (PDSB) Expected to Announce Quarterly Earnings on Wednesday - Defense World
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results - The Manila Times
PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright - Defense World
PDS Biotechnology at Life Sciences Virtual Investor Conference: Strategic Advances in Cancer Treatment - Investing.com Australia
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - Morningstar
PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer - Marketscreener.com
PDS Biotechnology Receives FDA Clearance for Versamune MUC1 Trial in Colon Cancer - Marketscreener.com
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer - The Manila Times
PDS Biotech Leadership to Participate in March Conferences - The Manila Times
PDS Biotechnology commences trial for head and neck squamous cell carcinoma - Yahoo
H.C. Wainwright maintains $21 target on PDS Biotech stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains $21 target on PDS Biotech stock - Investing.com India
HC Wainwright Reiterates “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB) - Defense World
PDS Biotech begins phase 3 trial for HPV cancer therapy By Investing.com - Investing.com Australia
PDS Biotech launches phase 3 trial for HPV cancer therapy By Investing.com - Investing.com Australia
PDS Biotech launches phase 3 trial for HPV cancer therapy - Investing.com India
PDS Biotech begins phase 3 trial for HPV cancer therapy - Investing.com India
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer - The Manila Times
Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors - The Globe and Mail
Understanding the Risks of Investing in PDS Biotechnology Corporation (PDSB) - Knox Daily
PDS Biotechnology’s Stephen Glover purchases $25,001 in common stock By Investing.com - Investing.com Canada
PDS Biotechnology director Gregory Freitag purchases $24,999 in stock By Investing.com - Investing.com Canada
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):